Last update 25 Oct 2025

Lu-177-DGUL

Overview

Basic Info

Drug Type
Peptide Conjugate Radionuclide, Therapeutic radiopharmaceuticals
Synonyms
177Lu-DOTA-GUL, Lu-177 labelled PSMA-D, PSMA-D GUL
Target
PSMA
Action
modulators
Mechanism
PSMA modulators(Prostate-specific membrane antigen modulators)
Therapeutic Areas
NeoplasmsUrogenital Diseases
Active Indication
Metastatic castration-resistant prostate cancer
Inactive Indication-
Originator Organization
Cellbion Co., Ltd.Cellbion Co., Ltd.
Active Organization
Cellbion Co., Ltd.Cellbion Co., Ltd.
Inactive Organization-
License Organization-
Drug Highest PhasePhase 1/2
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

Boost your research with our ADC technology data.
login
or
view full example data
Boost your research with our ADC technology data.

Related

2
Clinical Trials associated with Lu-177-DGUL
NCT05547061
/ Active, not recruitingPhase 1/2
A Phase 1/2 Clinical Trial to Evaluate the Safety, Tolerability, Dosimetry, and Anti-tumor Activity of Ga-68-NGUL / Lu-177-DGUL in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Refractory to Standard Therapy
IRCT20180113038331N1
/ RecruitingPhase 2IIT
Treatment of castration-resistant metastatic prostate cancer, refractory to routine treatment with Lu177-PSMA
100 Clinical Results associated with Lu-177-DGUL
Login to view more data
100 Translational Medicine associated with Lu-177-DGUL
Login to view more data
100 Patents (Medical) associated with Lu-177-DGUL
Login to view more data
100 Deals associated with Lu-177-DGUL
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Metastatic castration-resistant prostate cancerPhase 2
United States
Cellbion Co., Ltd.Cellbion Co., Ltd.
12 Apr 2021
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
SNMMI2023
Phase 1/2
Metastatic castration-resistant prostate cancer
PSMA-positive PET scan
28
177Lu-DGUL 5.55 GBq
frqmnbfgyt(zhzeojxcrj) = no severe adverse drug reactions were observed tltdzshrlk (iabgjpwhxx )
View more
Positive
28 Aug 2023
177Lu-DGUL 7.40 GBq
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free